NASDAQ:CANC Tema Oncology ETF (CANC) Price, Holdings, & News $27.43 -0.34 (-1.22%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$27.40 -0.02 (-0.09%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema Oncology ETF (NASDAQ:CANC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tema Oncology ETF alerts:Sign Up Key Stats Today's Range$27.37▼$27.8250-Day Range$25.08▼$27.7552-Week Range$20.10▼$29.81Volume8,925 shsAverage Volume15,216 shsMarket Capitalization$71.59 millionAssets Under Management$75.76 millionDividend Yield2.62%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema. Read More Tema Oncology ETF ExpensesTypeCANCTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.56%0.54%0.53%Other Expenses0.00%0.57%0.56%0.52%0.56%Total Expense0.99%0.74%0.76%0.73%0.73%Fee Waiver-0.24%-0.76%-0.66%-0.50%-0.63%Net Expense0.75%0.60%0.63%0.63%0.60% Receive CANC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Oncology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANC ETF News HeadlinesNo headlines for this company have been tracked by MarketBeat.com CANC ETF - Frequently Asked Questions How have CANC shares performed this year? Tema Oncology ETF's stock was trading at $24.31 at the beginning of 2025. Since then, CANC stock has increased by 12.8% and is now trading at $27.43. Who are Tema Oncology ETF's major shareholders? Tema Oncology ETF's top institutional investors include Thrivent Financial for Lutherans (36.68%) and Jane Street Group LLC (0.54%). How do I buy shares of Tema Oncology ETF? Shares of CANC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Oncology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Oncology ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), Nice (NICE) and Intellia Therapeutics (NTLA). Fund Details IssuerTema Global Fund NameTema Oncology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CANC Inception Date8/15/2023 Fund ManagerDavid Song WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings52 Fund Statistics Assets Under Management$75.76 million Average Daily Volume$0.00 Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest71,500 shs Miscellaneous Outstanding Shares2,610,000Beta1.11 Creation Unit10,000 Creation Fee$500.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 CANC HoldingsBridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 5.56%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 5.52%Roche (OTCMKTS:RHHBY)Holding Weight: 4.93%Novartis AGHolding Weight: 4.58%Merus (NASDAQ:MRUS)Holding Weight: 4.39%AstraZeneca PLCHolding Weight: 4.36%Genmab A/S (NASDAQ:GMAB)Holding Weight: 4.24%Eli Lilly and Company (NYSE:LLY)Holding Weight: 4.00%Nuvalent (NASDAQ:NUVL)Holding Weight: 3.13%Arcellx (NASDAQ:ACLX)Holding Weight: 3.08%Full Holdings DetailsCANC Sector ExposureCANC Industry Exposure This page (NASDAQ:CANC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
